In Ph‐like ALL, the patients with ABL‐derived may benefit from tyrosine kinase inhibitors (such as dasatinib), and those with JAK–STAT‐derived, from the addition of JAK inhibitors (such as ruxolitinib) to chemotherapy regimens [6, 7, 8, 9, 10, 11, 12, 13, 14]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.